Levetiracetam for mood stabilization and maintenance of seizure control following multiple treatment failure

Annals of Pharmacotherapy

Volumn 39, Issue 11, 2005, Pages 1928-1931

  Stoner, Steven C ^a,b   Lea, Jessica W ^a   Wolf, Angel L ^b   Berges, Arnaldo A ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b Northwest Missouri Psychiatric Rehabilitation Center   (United States)

Author keywords

Bipolar; Levetiracetam; Mood; Schizoaffective

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; CARBAMAZEPINE; CEFALEXIN; CLOMIPRAMINE; CLONIDINE; DOCUSATE SODIUM; ENALAPRIL; ETIRACETAM; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LACTULOSE; LEVOTHYROXINE; LORATADINE; MOOD STABILIZER; NALTREXONE; OXCARBAZEPINE; PALIPERIDONE; PAROXETINE; PRAVASTATIN; RISPERIDONE; TOPIRAMATE; TRAZODONE; TRIAMCINOLONE ACETONIDE; VALPROATE SEMISODIUM;

ADULT; ALCOHOLISM; ANTICONVULSANT THERAPY; ARTICLE; AUTOMUTILATION; BIPOLAR DISORDER; BORDERLINE STATE; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; DIARRHEA; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FECES INCONTINENCE; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERAMMONEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPONATREMIA; HYPOTHYROIDISM; LYMPHEDEMA; MAINTENANCE THERAPY; MORBID OBESITY; OSTEOARTHRITIS; PRIORITY JOURNAL; PSYCHOPATHY; SCHIZOAFFECTIVE PSYCHOSIS; SEIZURE;

ANTICONVULSANTS; CARBAMAZEPINE; DRUG THERAPY, COMBINATION; FEMALE; FRUCTOSE; HUMANS; MIDDLE AGED; MOOD DISORDERS; PIRACETAM; SEIZURES; TREATMENT OUTCOME; VALPROIC ACID;

EID: 27344438598     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G320     Document Type: Article

References (27)

1. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999;60:79-88.
2. Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000;61:841-50.
3. Calabrese JR, Keck PE, McElroy SL, Shelton MD. A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol 2001;21:340-2.
4. Vieta E, Torrent C, Garcia-Ribas G, Gilabert A, Garcia-Pares G, Rodriguez A, et al. Use of topiramate in treatment-resistant bipolar spectrum disorders. J Clin Psychopharmacol 2002;22:431-5.
5. Suppes T. Review of the use of topiramate for treatment of bipolar disorders. J Clin Psychopharmacol 2002;22:599-609.
6. Maidment ID. The use of topiramate in mood stabilization. Ann Pharmacother 2002;36:1277-81. DOI 10.1345/aph.1A398
7. Nasr S. Oxcarbazepine for mood disorders (letter). Am J Psychiatry 2002;159:1793.
8. Goldberg JF, Burdick KE. Levetiracetam for acute mania (letter). Am J Psychiatry 2002;159:148.
9. Grunze H, Langosch J, Born C, Schaub G, Walden J. Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J Clin Psychiatry 2003;64:781-4.
10. Post RM, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE, et al. Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. J Clin Psychiatry 2005;66:370-4.
11. Evins AE. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J Clin Psychiatry 2003;64(suppl 8):9-14.
12. Meador KJ. Newer anticonvulsants: dosing strategies and cognition in treating patients with mood disorders and epilepsy. J Clin Psychiatry 2003;64(suppl 8):30-4.
13. White HS. Mechanism of action of newer anticonvulsants. J Clin Psychiatry 2003;64(suppl 8):5-8.
14. Schatzberg AF. Employing pharmacologic treatment of bipolar disorder to greatest effect. J Clin Psychiatry 2004;65(suppl 15):15-20.
15. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
16. Package insert. Risperdal (risperidone). Titusville, NJ: Janssen Pharmaceuticals, December 2003.
17. Grikiniene J, Voldemaras V, Stakisaitis D. Gender differences of sodium metabolism and hyponatremia as an adverse drug effect. Medicina 2004;40:935-42.
18. Package insert. Tegretol (carbamazepine). East Hanover, NJ: Novartis Pharmaceutical, September 2003.
19. Sachdeo RC, Wasserstein A, Mesenbrink PJ, D'Souza J. Effects of oxcarbazepine on sodium and water concentration handling. Ann Neurol 2002;51:613-20.
20. Isojarvi JI, Huuskonen UE, Pakarinen AJ, Vuolteenaho O, Myllyla W. The regulation of serum sodium after replacing carbamazepine with oxcarbazepine. Epilepsia 2001;42:741-5.
21. Package insert. Topamax (topiramate). Raritan, NJ: Ortho-McNeil Pharmaceuticals, August 2004.
22. Tatum WO, French JA, Faught E, Morris GL, Liporace J, Kanner A, et al. Postmarketing experience with topiramate and cognition. Epilepsia 2001;42:1134-40.
23. Package insert. Depakote (divalproex sodium). North Chicago, IL: Abbott Laboratories, September 2004.
24. Mallet L. Valproic acid induced hyperammonemia and thrombocytopenia in an elderly woman. Ann Pharmacother 2004;38:1643-7. Epub 17 Aug 2004. DOI 10.1345/aph.1E063
25. Package insert. Trileptal (oxcarbazepine). Suffern, NY: Novartis Pharmaceutical, March 2004.
26. Schmidt D, Arroyo S, Baulac M, Dam M, Dulac O, Friis M, et al. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view, Acta Neurol Scand 2001;104:167-70.
27. Package insert. Keppra (levetiracetam). Smyrna, GA: UCB Pharma, December 2004.